YMAB — Y-mAbs Therapeutics Share News
0.000.00%
Last trade - 00:00- $390.32m
- $328.02m
- $87.69m
Y-mAbs Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP: Boston Beer Company, Inter Parfums, Netflix
Brief: Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh As Chief Financial Officer
Brief: Y-Mabs Therapeutics Entered Into A Stipulation And Agreement Of Settlement
Brief: Y-mAbs Appoints Norman LaFrance As Chief Development Officer
Y-mAbs Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Live Markets: Big pharma's FOMO will lead to more radio M&A
U.S. STOCKS ON THE MOVE-Robinhood Markets, ADM, Vaalco Energy
Y-mAbs Therapeutics falls after CFO steps down
Brief: Y-mAbs Appoints Oncology Executive Mary Tagliaferri TO Board
U.S. STOCKS ON THE MOVE-Madrigal Pharma, Copper miners, NetApp
U.S. STOCKS ON THE MOVE-Cooper, US energy stocks, Vista Outdoor
U.S. STOCKS ON THE MOVE-Old Republic, TDCX, Repay Holdings
Y-mAbs jumps on Q4 revenue beat
Y-mAbs Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Y-mAbs Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Y-Mabs Therapeutics Maintaining Its Previous Financial Guidance For Year Ended Dec. 31, 2023
Brief: Y-mAbs Therapeutics Q3 Net Income USD -7.7 Million
Brief: Y-Mabs Names Michael Rossi As President And Chief Executive Officer And Director